Welcome to CDC stacks | Rapid Emergence of Oseltamivir Resistance - 7946 | Emerging Infectious Diseases | CDC Public Access
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Rapid Emergence of Oseltamivir Resistance
  • Published Date:
    Apr 2010
  • Source:
    Emerg Infect Dis. 16(4):723-725.
Filetype[PDF-142.76 KB]


No Related Documents.
You May Also Like:
  1. H275Y Mutant Pandemic (H1N1) 2009 Virus in Immunocompromised Patients
    Personal Author:
    Renaud, Christian; Boudreault, Alexandre A.; Kuypers, Jane; Lofy, Kathryn H.; Corey, Lawrence; Boeckh, Michael J.; Englund, Janet A.;
    Published:
    Apr 2011
    Source:
    Emerg Infect Dis. 17(4):653-660.
    Description:
    Most oseltamivir-resistant pandemic (H1N1) 2009 viruses have been isolated from immunocompromised patients. To describe the clinical features, treatment, outcomes, and virologic data associated with infection from pandemic (H1N1) 2009 virus with H275...
    File Type:
    Filetype[PDF - 420.34 KB]
  2. Emergence of Oseltamivir-Resistant Pandemic (H1N1) 2009 Virus within 48 Hours
    Personal Author:
    Inoue, Masafumi; Barkham, Timothy; Leo, Yee-Sin; Chan, Kwai-Peng; Chow, Angela; Wong, Christopher W.; Lee, Raphael Tze-Chuen; Maurer-Stroh, Sebastian; Lin, Raymond; Lin, Cui;
    Published:
    Oct 2010
    Source:
    Emerg Infect Dis. 16(10):1633-1636.
    Description:
    An oseltamivir-resistant influenza A pandemic (H1N1) 2009 virus evolved and emerged from zero to 52% of detectable virus within 48 hours of a patient's exposure to oseltamivir. Phylogenetic analysis and data gathered by pyrosequencing and cloning dir...
    File Type:
    Filetype[PDF - 384.84 KB]
  3. Antiviral Drugs for Treatment of Patients Infected with Pandemic (H1N1) 2009 Virus
    Personal Author:
    Hartley, David M.; Nelson, Noele P.; Perencevich, Eli N.;
    Published:
    Nov 2009
    Source:
    Emerg Infect Dis. 15(11):1851-1852.
    File Type:
    Filetype[PDF - 143.42 KB]
  4. Monitoring and Characterization of Oseltamivir-Resistant Pandemic (H1N1) 2009 Virus, Japan, 2009–2010
    Personal Author:
    Ujike, Makoto; Ejima, Miho; Anraku, Akane; Shimabukuro, Kozue; Obuchi, Masatsugu; Kishida, Noriko; Hong, Xu; Takashita, Emi; Fujisaki, Seiichiro; Yamashita, Kazuyo; Horikawa, Hiroshi; Kato, Yumiko; Oguchi, Akio; Fujita, Nobuyuki; Tashiro, Masato; Odagiri, Takato;
    Corporate Author:
    Influenza Virus Surveillance Group of Japan
    Published:
    Mar 2011
    Source:
    Emerg Infect Dis. 17(3):470-479.
    Description:
    To monitor and characterize oseltamivir-resistant (OR) pandemic (H1N1) 2009 virus with the H275Y mutation, we analyzed 4,307 clinical specimens from Japan by neuraminidase (NA) sequencing or inhibition assay; 61 OR pandemic (H1N1) 2009 viruses were d...
    File Type:
    Filetype[PDF - 457.07 KB]
  5. Triple Combination Antiviral Drug (TCAD) Composed of Amantadine, Oseltamivir, and Ribavirin Impedes the Selection of Drug-Resistant Influenza A Virus
    Personal Author:
    Hoopes, Justin D.; Driebe, Elizabeth M.; Kelley, Erin; Engelthaler, David M.; Keim, Paul S.; Perelson, Alan S.; Rong, Libin; Went, Gregory T.; Nguyen, Jack T.;
    Published:
    Dec 29 2011
    Source:
    PLoS One. 2011; 6(12).
    Description:
    Widespread resistance among circulating influenza A strains to at least one of the anti-influenza drugs is a major public health concern. A triple combination antiviral drug (TCAD) regimen comprised of amantadine, oseltamivir, and ribavirin has been ...
    File Type:
    Filetype[PDF - 582.83 KB]